Legend Biotech (LEGN) Expected to Post Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Legend Biotech to post earnings of $0.01 per share and revenue of $361.46 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Tuesday, August 11th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. The company had revenue of $387.50 million during the quarter, compared to analysts’ expectations of $355.96 million. Legend Biotech had a negative return on equity of 8.71% and a negative net margin of 7.21%. The firm’s revenue for the quarter was up 51.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS. On average, analysts expect Legend Biotech to post ($0.08) EPS for the current fiscal year and $1.16 EPS for the next fiscal year.

Legend Biotech Trading Up 1.4%

LEGN traded up $0.29 during trading on Tuesday, reaching $21.39. The stock had a trading volume of 308,357 shares, compared to its average volume of 2,383,198. The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of -85.68 and a beta of 0.57. The stock’s 50 day moving average is $19.54 and its two-hundred day moving average is $22.11. Legend Biotech has a one year low of $16.24 and a one year high of $37.50.

Analyst Ratings Changes

LEGN has been the subject of several research reports. Raymond James Financial reiterated an “outperform” rating and issued a $58.00 price target on shares of Legend Biotech in a research note on Monday, July 27th. HC Wainwright restated a “buy” rating on shares of Legend Biotech in a report on Friday. Oppenheimer downgraded shares of Legend Biotech from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $75.00 to $40.00 in a research note on Wednesday, August 12th. Weiss Ratings downgraded Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Finally, Royal Bank Of Canada reduced their price objective on Legend Biotech from $58.00 to $56.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $54.69.

Insider Activity

In other news, CFO Carlos Santos sold 5,430 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $9.14, for a total value of $49,630.20. Following the transaction, the chief financial officer owned 14,246 shares in the company, valued at approximately $130,208.44. This represents a 27.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total transaction of $258,920.20. Following the sale, the director owned 52,731 shares in the company, valued at approximately $498,835.26. The trade was a 34.17% decrease in their position. The SEC filing for this sale provides additional information. 0.02% of the stock is currently owned by insiders.

About Legend Biotech

Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. The company’s primary technology is chimeric antigen receptor T-cell (CAR-T) therapy, which genetically modifies a patient’s immune cells to recognize and attack cancer cells.

Legend Biotech’s leading product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma.